MSD launches blockbuster cancer drug Keytruda in India

US biopharmaceutical giant Merck, Sharpe and Dohme (MSD) has launched its blockbuster cancer drug ‘Keytruda’ (pembrolizumab) in India around a year after it first received approvals to market it, said persons aware of the development. The drug has so far only been approved here for a less prevalent type of cancer, while it is marketed in countries like the US to treat additional indications like a specific kind of lung cancer. 

Keytruda, hailed as a ‘gamechanger’ therapy in oncology,, is expected to help the immune system identify and selectively combat only cancerous cells instead of aggressively attacking cancer cells and risking healthy tissues in the process like existing therapies. The drug generated global sales of $1.4 billion during 2016. 


The Drug Controller General of India (DCGI) gave MSD permission to market Keytruda in June 2016, according to minutes of the regulator’s Subject Expert Committee on oncology and haematology. 

A person close to the development said the company had applied for approvals in India for unresectable or metastatic melanoma — types of malignant skin cancers that either cannot be removed by surgery or have spread to other parts of the body. In countries like the US, Keytruda is approved for other types of cancers, including non-small cell lung cancer (NSCLC). 


Keytruda is expected to be 30% cheaper than the global prices and cost Rs 3.75-4.5 lakh for each dose here, according to two industry insiders who spoke to ET on condition of anonymity. The drug was launched in the US in 2014 at a price of reportedly $12,500 for each patient monthly or $150,000 annually. MSD did not respond to ET’s queries about the roll-out and pricing by the time this story went to press. 


Oncologists expect MSD to approach the apex drug regulator to extend its approval for Keytruda to additional indications, including NSCLC, now that it has launched the product here. 

“The results of key trials (with Keytruda) are so robust and encouraging,” said Dr Sachin Almel, consultant medical oncologist, Hinduja Hospital and Medical Research Centre, Mumbai. He expects MSD to soon apply for approvals for at least NSCLC as well. 

Incidence of melanoma in India is less than 1% compared to other cancers, according to Almel. In comparison, NSCLC is “fairly common” and contributes to roughly 3-5% of all cancers in the country, he added. 

At the same time, the potentially ‘breakthrough’ drug may not be able to create much impact because it is too expensive. 

“Only one in 1,000 of my patients can actually afford to use this drug,” said an oncologist who spoke to ET on condition of anonymity. 

Source:http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/msd-launches-blockbuster-cancer-drug-keytruda-in-india/articleshow/60487138.cms

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more